Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.17 is 75% above its 5-year average of -4.74, near the high end of its 5-year range (-14.07–-1.07).
59.38% above its 12-month average of -2.88.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.07.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.17
EARNINGS PER SHARE (EPS) AVG TTM
-2.88
EARNINGS PER SHARE (EPS) AVG 3Y
-6.48
EARNINGS PER SHARE (EPS) AVG 5Y
-4.74
EARNINGS PER SHARE (EPS) AVG 10Y
-3.00
EARNINGS PER SHARE (EPS) AVG 15Y
-0.97
EARNINGS PER SHARE (EPS) AVG 20Y
-1.05
CURRENT VS TTM AVG
+59.38%
CURRENT VS 3Y AVG
+81.94%
CURRENT VS 5Y AVG
+75.29%
CURRENT VS 10Y AVG
+60.94%
CURRENT VS 15Y AVG
-20.52%
CURRENT VS 20Y AVG
-11.93%
Inovio Pharmaceuticals, Inc.
Market Cap
$80.49M
Earnings Per Share (EPS)
-1.17
TTM Avg
-2.88
3Y Avg
-6.48
5Y Avg
-4.74
Market Cap
$75.58M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.44
3Y Avg
-0.60
5Y Avg
-0.58
Market Cap
$81.31M
Earnings Per Share (EPS)
-1.15
TTM Avg
-1.39
3Y Avg
-1.49
5Y Avg
-1.37
Market Cap
$76.74M
Earnings Per Share (EPS)
-0.38
TTM Avg
-0.49
3Y Avg
-0.66
5Y Avg
-0.75
Market Cap
$84.52M
Earnings Per Share (EPS)
-1.18
TTM Avg
-4.40
3Y Avg
-32.48
5Y Avg
-54.06
Market Cap
$84.87M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$85.90M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
Market Cap
$81.82M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.32
3Y Avg
-0.23
5Y Avg
-0.23
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | $80.49M | -1.17 | -2.88 | -6.48 | -4.74 |
| MindWalk Holdings Corp. (HYFT)vs › | $75.58M | -0.26 | -0.44 | -0.60 | -0.58 |
| Pulmonx Corporation (LUNG)vs › | $81.31M | -1.15 | -1.39 | -1.49 | -1.37 |
| Hyperfine, Inc. (HYPR)vs › | $76.74M | -0.38 | -0.49 | -0.66 | -0.75 |
| LENSAR Inc (LNSR)vs › | $81.67M | N/A | -2.80 | -2.22 | -2.13 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.52M | -1.18 | -4.40 | -32.48 | -54.06 |
| Humacyte, Inc. (HUMA)vs › | $84.87M | -0.51 | -0.76 | -0.68 | -1.48 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.90M | -0.19 | -0.58 | -0.69 | -0.67 |
| Citius Oncology, Inc. (CTOR)vs › | $81.82M | -0.48 | -0.32 | -0.23 | -0.23 |
| Gain Therapeutics, Inc. (GANX)vs › | $74.00M | -0.50 | -0.75 | -1.17 | -1.06 |
Trailing EPS (TTM)
$-1.17
Forward EPS (Est.)
$-0.76
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.81 |
| 2024-12-31 | -3.95 |
| 2023-12-31 | -6.09 |
| 2022-12-31 | -14.07 |
| 2021-12-31 | -1.42 |
| 2020-12-31 | -1.07 |
| 2019-12-31 | -0.97 |
| 2018-12-31 | -1.05 |
| 2017-12-31 | -1.08 |
| 2016-12-31 | -1.01 |
| 2015-12-31 | -0.43 |
| 2014-12-31 | -0.61 |
| 2013-12-31 | -1.43 |
| 2012-12-31 | -0.58 |
| 2011-12-31 | -0.48 |
| 2010-12-31 | -0.68 |
| 2009-12-31 | -1.31 |
| 2008-12-31 | -1.18 |
| 2007-12-31 | -1.08 |
| 2006-12-31 | -1.58 |
| 2005-12-31 | -3.22 |
| 2004-12-31 | -2.49 |
| 2003-12-31 | -1.40 |
| 2002-12-31 | -2.35 |
| 2001-12-31 | -5.13 |
| 2000-12-31 | -6.80 |
| 1999-12-31 | -5.21 |
